GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road,

> Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494

Web: www.gsk-india.com Email: askus@gsk.com

6th December 2023

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East)

Mumbai - 400051

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received below mentioned orders.

Sr	Name of the author	Nature and details of	Date of receipt of	Details of violation	Impact on financial,
no		the action(s) taken, initiated o	direction or order,	(s) / contravention	operation or other
		order(s) passed	including any	(s) committed or	activities of the listed
			ad-interim or interim	alleged to be	entity, quantifiable
			orders, or any	committed	in monetary terms
			other		to the extent possible
			communication		
			from the authority		
1	TDS CPC, Aaykar Bhavan, Sector-3, Vaishali, Ghaziabad UP - 201010	Interest Demand raised for Rs 21,41,865/- for the late payment of TDS for the month of Sept-2023	5 th December 2023		No impact on the
				Delay in making the TDS payment on Salary for Sept '23	Company as the
					delay is due to
					Bank's server
					technical glitch where
					the date of payment
					in challan is captured
					incorrectly. GSK
					will apply for the
					rectification of
					Demand Intimation.
2	ACIT issued the Assessment Order u/s 143(3) r.w.	Demand raised for Rs 19.45/- Crores after disallowing some	17 th November 2023	Some expenses	GSK will further
				were disallowed	appeal this matter at
				and Adjustments	the 1 st appellate
				made under	authority challenging
	Section 144C (3)	expenses and making	14070111001 2020	Transfer	the Assessing Officer
	for the AY	adjustments in		Pricing for Group	Order and hence no
	2020-2021.	Transfer Pricing		Company	financial impact is
				transaction.	assessed at this time.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary

CIN: L24239MH1924PLC001151